DrugBank

SEPTEMBER 12, 2024

At DrugBank we’re committed to improving your daily research and drug development operations. Data Exploration If you’re venturing into a new area of drug research, the Data Dictionary helps you identify relevant data fields and understand their context.

Production 98

Production Government Packaging Research 98

DrugBank

MAY 15, 2024

Its structure makes it incredibly difficult for drugs to bind effectively, which has stymied drug development for decades. The binding pockets on KRAS are shallow and polar , not ideal for the kinds of interactions needed for strong, effective drug binding.

Small Molecule 98

Small Molecule Molecular Biology Drugs Disease 98

Advarra

AUGUST 16, 2022

The Orphan Drug Act of 1983 was instrumental in changing the number of orphan drugs approved in the U.S. The law established the Office of Orphan Products Development , providing financial incentives for pharmaceutical companies to develop orphan drugs and making it more viable to invest in orphan drug research and development.

Disease 52

Disease Clinical Trials FDA Approval FDA 52

The Pharma Data

NOVEMBER 10, 2020

Growing into a biopharmaceutical company, Innovent has built an integrated platform covering from drug discovery, CMC, clinical development and commercialization. Dr. Liu shared his over 30 years of R&D experience in drug development both in the global pharmaceutical companies and world renowned scientific research institutions.

Biosimilars 52

Biosimilars Clinical Trials International Clinical Development 52

Conversations in Drug Development Trends

FEBRUARY 21, 2024

The on-site cGMP Phase 1 pharmacy must have radiolabel drug preparation experience A clinical pharmacology unit (CPU) must be licensed and experienced in handling radioactive investigational drugs in order to complete your AME study.

Clinical Trials 80

Clinical Trials Pharmacy Clinical Pharmacology FDA 80

Agency IQ

JUNE 9, 2023

The Orphan Regulation entered into force in January, 2000, outlining requirements for orphan designation and incentives, and establishing the EMA Committee for Orphan Medicinal Products (COMP). Unmet medical need requires the disease to remain associated with high morbidity or mortality if a product is approved for that condition.

Marketing 40

Marketing Regulations Biosimilars Drugs 40

Codon

JUNE 2, 2024

However, the original research mission was a casualty of this pivot, as the top priority of JAX became the mass production of standardized mice for sale. This is in contrast to even the best colony management production practices, which result in about 3 generations per year—about 300 generations over a 100-year period.

Laboratories 136

Laboratories Research Disease Science 136